EISAI INC. for EISAI INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Patient access to medicines in Medicaid including rebate, waiver policy and funding issues. Access to medicines in Medicare; proposed rule on testing of Medicare part B prescription drug models; rebates and Medicare part D - provisions on HHS-OIG Rebate Safe Harbor. Amending protected classes in Medicare. Clarifying or reforming 340B program. Value-based drug contracting. Prescription drug vial sizes. Drug pricing. Co-pay accumulators. Global pharmaceutical supply chain operations and manufacturing locations. Bayh-Dole march-in rights. Medicare Part D Negotiation/Non-Interference Repeal. Medicare Part D Redesign. Notice of Benefit and Payment Parameters. Proposed Medicaid Regulation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BADGLEY New | — |
| TRICIA BROOKS New | — |
Medicare/Medicaid MMM
Patient access to medicines in Medicaid including rebate, waiver policy and funding issues. Access to medicines in Medicare; proposed rule on testing of Medicare part B prescription drug models; rebates and Medicare part D - provisions on HHS-OIG Rebate Safe Harbor. Amending protected classes in Medicare. Clarifying or reforming 340B program. Value-based drug contracting. Prescription drug vial sizes. Drug pricing. Co-pay accumulators. Global pharmaceutical supply chain operations and manufacturing locations. Bayh-Dole march-in rights. Medicare Part D Negotiation/Non-Interference Repeal. Medicare Part D Redesign. Notice of Benefit and Payment Parameters. Proposed Medicaid Regulation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BADGLEY New | — |
| TRICIA BROOKS New | — |
Medical/Disease Research/Clinical Labs MED
Patient access to medicines in Medicaid including rebate, waiver policy and funding issues. Access to medicines in Medicare; proposed rule on testing of Medicare part B prescription drug models; rebates and Medicare part D - provisions on HHS-OIG Rebate Safe Harbor. Amending protected classes in Medicare. Clarifying or reforming 340B program. Value-based drug contracting. Prescription drug vial sizes. Drug pricing. Co-pay accumulators. Global pharmaceutical supply chain operations and manufacturing locations. Bayh-Dole march-in rights. Medicare Part D Negotiation/Non-Interference Repeal. Medicare Part D Redesign. Notice of Benefit and Payment Parameters. Proposed Medicaid Regulation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BADGLEY New | — |
| TRICIA BROOKS New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| EISAI CO. LTD. | Japan | Japan | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.